抗血管内皮生长因子疗法市场－全球产业规模、份额、趋势、机会和预测，按产品、疾病、最终用户、地区和竞争格局划分，2020-2030年预测

2024年全球抗血管内皮生长因子（VEGF）疗法市场规模为143.8亿美元，预计2030年将以3.65%的复合年增长率成长至178.3亿美元。抗VEGF疗法是一类生物製剂，旨在抑制新血管的形成，而新血管的形成是多种疾病进展的关键过程。这些疗法主要用于治疗眼科疾病，例如老年黄斑部病变和糖尿病性黄斑水肿，以及多种癌症。

主要市场驱动因素

全球眼科疾病，特别是老年黄斑部病变（AMD）和糖尿病黄斑水肿（DME）的日益流行，极大地推动了抗血管内皮生长因子疗法市场的发展。这些致盲性疾病是全球失明和严重视力障碍的主要原因，因此亟需有效且持续的药物介入。

主要市场挑战

全球抗血管内皮生长因子疗法市场面临多种成熟生物製剂专利即将到期的严峻挑战。预计这种情况将加剧生物相似药之间的竞争，从而直接影响原厂药生产商的市场动态。

主要市场趋势

全球抗血管内皮生长因子（VEGF）疗法市场受到抗VEGF生物相似药市场渗透率不断提高的显着影响。这一趋势的驱动力在于提高成本效益并扩大患者获得关键疗法的机会，尤其是在主要原研究生物製剂专利即将到期的情况下。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球抗血管内皮生长因子疗法市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 副产品（Eylea、Lucentis、Beovu）
  • 依疾病分类（黄斑水肿、糖尿病视网膜病变、视网膜静脉阻塞、老年黄斑部病变）
  • 依最终使用者（医院和诊所、门诊中心、其他）划分
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美抗血管内皮生长因子疗法市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲抗血管内皮生长因子疗法市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区抗血管内皮生长因子疗法市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲抗血管内皮生长因子疗法市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲抗血管内皮生长因子疗法市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球抗血管内皮生长因子疗法市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• F. Hoffmann-La Roche Ltd.
• Biogen MA Inc.
• Pfizer Inc.
• Coherus BioSciences, Inc.
• Amgen Inc.
• Viatris Inc.
• Bausch Health Companies Inc.
• Novartis AG
• Regeneron Pharmaceuticals Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, valued at USD 14.38 Billion in 2024, is projected to experience a CAGR of 3.65% to reach USD 17.83 Billion by 2030. Anti-vascular endothelial growth factor (VEGF) therapeutics are a class of biological drugs designed to inhibit the formation of new blood vessels, a process crucial in the progression of various diseases. These therapies are predominantly utilized in the treatment of ophthalmic conditions, such as age-related macular degeneration and diabetic macular edema, as well as several types of cancer.

Key Market Drivers

The escalating global prevalence of ophthalmic diseases, particularly age-related macular degeneration (AMD) and diabetic macular edema (DME), serves as a substantial impetus for the anti-vascular endothelial growth factor therapeutics market. These debilitating conditions, which are leading causes of blindness and severe vision impairment worldwide, necessitate effective and sustained pharmacological intervention. Enhanced diagnostic capabilities and improved patient access to ophthalmological care contribute to a larger identified patient pool requiring treatment.

Key Market Challenges

The global anti-vascular endothelial growth factor therapeutics market faces a significant challenge from the impending patent expirations of several established biological drugs. This scenario is expected to intensify biosimilar competition, which directly influences the market dynamics for originator manufacturers. As biosimilar versions become available, they enter the market at considerably lower prices to gain market share. This increased competition drives down the average selling prices across the entire product class.

Key Market Trends

The Global Anti-Vascular Endothelial Growth Factor (VEGF) Therapeutics Market is significantly shaped by the expanding market penetration of anti-VEGF biosimilars. This trend is driven by the imperative to enhance cost-effectiveness and broaden patient access to critical therapies, particularly as key originator biologics face patent expirations. Biosimilars introduce robust price competition, thereby fostering greater affordability and increasing the overall volume of anti-VEGF treatments dispensed.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Biogen MA Inc.
• Pfizer Inc.
• Coherus BioSciences, Inc.
• Amgen Inc.
• Viatris Inc.
• Bausch Health Companies Inc.
• Novartis AG
• Regeneron Pharmaceuticals Inc.

Report Scope:

In this report, the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Product:

• Eylea
• Lucentis
• Beovu

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Disease:

• Macular Edema
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Age-related Macular Degeneration

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By End Users:

• Hospitals & Clinics
• Ambulatory Care centers
• Others

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market.

Available Customizations:

Global Anti-Vascular Endothelial Growth Factor Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Eylea, Lucentis, Beovu)
  • 5.2.2. By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration)
  • 5.2.3. By End Users (Hospitals & Clinics, Ambulatory Care centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Disease
  • 6.2.3. By End Users
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Disease
      • 6.3.1.2.3. By End Users
  • 6.3.2. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Disease
      • 6.3.2.2.3. By End Users
  • 6.3.3. Mexico Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Disease
      • 6.3.3.2.3. By End Users

7. Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Disease
  • 7.2.3. By End Users
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Disease
      • 7.3.1.2.3. By End Users
  • 7.3.2. France Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Disease
      • 7.3.2.2.3. By End Users
  • 7.3.3. United Kingdom Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Disease
      • 7.3.3.2.3. By End Users
  • 7.3.4. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Disease
      • 7.3.4.2.3. By End Users
  • 7.3.5. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Disease
      • 7.3.5.2.3. By End Users

8. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Disease
  • 8.2.3. By End Users
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Disease
      • 8.3.1.2.3. By End Users
  • 8.3.2. India Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Disease
      • 8.3.2.2.3. By End Users
  • 8.3.3. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Disease
      • 8.3.3.2.3. By End Users
  • 8.3.4. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Disease
      • 8.3.4.2.3. By End Users
  • 8.3.5. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Disease
      • 8.3.5.2.3. By End Users

9. Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Disease
  • 9.2.3. By End Users
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Disease
      • 9.3.1.2.3. By End Users
  • 9.3.2. UAE Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Disease
      • 9.3.2.2.3. By End Users
  • 9.3.3. South Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Disease
      • 9.3.3.2.3. By End Users

10. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Disease
  • 10.2.3. By End Users
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Disease
      • 10.3.1.2.3. By End Users
  • 10.3.2. Colombia Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Disease
      • 10.3.2.2.3. By End Users
  • 10.3.3. Argentina Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Disease
      • 10.3.3.2.3. By End Users

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Biogen MA Inc.
• 15.3. Pfizer Inc.
• 15.4. Coherus BioSciences, Inc.
• 15.5. Amgen Inc.
• 15.6. Viatris Inc.
• 15.7. Bausch Health Companies Inc.
• 15.8. Novartis AG
• 15.9. Regeneron Pharmaceuticals Inc.

16. Strategic Recommendations

17. About Us & Disclaimer